Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 17

1.

The impact of free trial acceptance on demand for alternative nicotine products: evidence from experimental auctions.

Rousu MC, O'Connor RJ, Bansal-Travers M, Pitcavage JM, Thrasher JF.

Harm Reduct J. 2015 Jun 11;12:18. doi: 10.1186/s12954-015-0052-3.

2.

A fresh look at tobacco harm reduction: the case for the electronic cigarette.

Polosa R, Rodu B, Caponnetto P, Maglia M, Raciti C.

Harm Reduct J. 2013 Oct 4;10:19. doi: 10.1186/1477-7517-10-19. Review.

3.

Use of conventional and novel smokeless tobacco products among US adolescents.

Agaku IT, Ayo-Yusuf OA, Vardavas CI, Alpert HR, Connolly GN.

Pediatrics. 2013 Sep;132(3):e578-86. doi: 10.1542/peds.2013-0843. Epub 2013 Aug 5.

4.

The development and psychometric evaluation of the Smokeless Tobacco Expectancies Scale (STES).

Gottlieb JC, Cohen LM, Demarree KG, Treloar HR, McCarthy DM.

Psychol Assess. 2013 Sep;25(3):997-1001. doi: 10.1037/a0032256. Epub 2013 Apr 1.

5.

Subjective responses to oral tobacco products: scale validation.

Hatsukami DK, Zhang Y, O'Connor RJ, Severson HH.

Nicotine Tob Res. 2013 Jul;15(7):1259-64. doi: 10.1093/ntr/nts265. Epub 2012 Dec 13.

6.

The ratio of a urinary tobacco-specific lung carcinogen metabolite to cotinine is significantly higher in passive than in active smokers.

Vogel RI, Carmella SG, Stepanov I, Hatsukami DK, Hecht SS.

Biomarkers. 2011 Sep;16(6):491-7. doi: 10.3109/1354750X.2011.598565. Epub 2011 Aug 3.

7.

The scientific foundation for tobacco harm reduction, 2006-2011.

Rodu B.

Harm Reduct J. 2011 Jul 29;8:19. doi: 10.1186/1477-7517-8-19.

8.

Retail promotions and perceptions of R.J. Reynolds' novel dissolvable tobacco in a US test market.

Romito LM, Saxton MK, Coan LL, Christen AG.

Harm Reduct J. 2011 May 15;8:10. doi: 10.1186/1477-7517-8-10.

9.

Effect of oral snus and medicinal nicotine in smokers on toxicant exposure and withdrawal symptoms: a feasibility study.

Kotlyar M, Hertsgaard LA, Lindgren BR, Jensen JA, Carmella SG, Stepanov I, Murphy SE, Hecht SS, Hatsukami DK.

Cancer Epidemiol Biomarkers Prev. 2011 Jan;20(1):91-100. doi: 10.1158/1055-9965.EPI-10-0349. Epub 2010 Nov 10. Erratum in: Cancer Epidemiol Biomarkers Prev. 2011 May;20(5):1048.

10.

The use of snus for quitting smoking compared with medicinal products.

Lund KE, McNeill A, Scheffels J.

Nicotine Tob Res. 2010 Aug;12(8):817-22. doi: 10.1093/ntr/ntq105. Epub 2010 Jul 9.

11.

A pilot randomized study of smokeless tobacco use among smokers not interested in quitting: changes in smoking behavior and readiness to quit.

Carpenter MJ, Gray KM.

Nicotine Tob Res. 2010 Feb;12(2):136-43. doi: 10.1093/ntr/ntp186. Epub 2010 Jan 6.

12.

Abuse liability assessment of tobacco products including potential reduced exposure products.

Carter LP, Stitzer ML, Henningfield JE, O'Connor RJ, Cummings KM, Hatsukami DK.

Cancer Epidemiol Biomarkers Prev. 2009 Dec;18(12):3241-62. doi: 10.1158/1055-9965.EPI-09-0948. Review.

13.

Measures for assessing subjective effects of potential reduced-exposure products.

Hanson K, O'Connor R, Hatsukami D.

Cancer Epidemiol Biomarkers Prev. 2009 Dec;18(12):3209-24. doi: 10.1158/1055-9965.EPI-09-0971. Review.

14.

Clinical trials methods for evaluation of potential reduced exposure products.

Hatsukami DK, Hanson K, Briggs A, Parascandola M, Genkinger JM, O'Connor R, Shields PG.

Cancer Epidemiol Biomarkers Prev. 2009 Dec;18(12):3143-95. doi: 10.1158/1055-9965.EPI-09-0654. Review.

15.

Transdisciplinary Tobacco Use Research Centers: research achievements and future implications.

Baker TB, Cummings KM, Hatsukami DK, Johnson CA, Lerman C, Niaura R, O'Malley SS.

Nicotine Tob Res. 2009 Oct;11(10):1231-44. doi: 10.1093/ntr/ntp112. Epub 2009 Jul 24. No abstract available.

16.

The Strategic Dialogue on Tobacco Harm Reduction: a vision and blueprint for action in the US.

Zeller M, Hatsukami D; Strategic Dialogue on Tobacco Harm Reduction Group.

Tob Control. 2009 Aug;18(4):324-32. doi: 10.1136/tc.2008.027318. Epub 2009 Feb 24.

17.

Developing the science base for reducing tobacco harm.

Hatsukami DK, Joseph AM, Lesage M, Jensen J, Murphy SE, Pentel PR, Kotlyar M, Borgida E, Le C, Hecht SS.

Nicotine Tob Res. 2007 Nov;9 Suppl 4:S537-53. doi: 10.1080/14622200701679040. Review.

Supplemental Content

Support Center